| |
|
|
Session 65
Poster Presentations Pharmacology of Novel Antiretroviral Agents Wednesday 1:30 - 3:30 pm Hall A |
| 546-A | The Preclinical Pharmacokinetics and Safety Pharmacology of the Anti-HIV CCR5 Antagonist, UK-427, 857 C. Napier*1, P. Dorr1, R. Gladue2, R. Halliday1, D. Leishman1, I. Machin1, R. Mitchell1, A. Nedderman1, M. Perros1, S. Roffey1, D. Walker1, R. Webster1 1Pfizer Global R&D, Sandwich Labs, Kent, UK and 2Pfizer Global R&D, Groton Labs, CT |
| 547 | Pharmacokinetics of Single and Multiple Oral Doses of UK-427,857-A Novel CCR5 Antagonist in Healthy Volunteers S. Abel*, E. Van der Ryst, G. J. Muirhead, M. Rosario, A. Edgington, G. Weissgerber Pfizer Global Research and Dev, Sandwich Labs, Kent, UK |
| 549 | TMC114, A Next Generation HIV Protease Inhibitor: Pharmacokinetics and Safety Following Oral Administration of Multiple Doses With and Without Low Doses of Ritonavir in Healthy Volunteers R. Hoetelmans*1, I. Van der Sandt2, M. De Pauw1, K. Struble3, M. Peeters1, R. Van der Geest1 1Tibotec, Mechelen, Belgium; 2Kinesis, Breda, The Netherlands; and 3Tibotec-Virco, Durham, NC |
| 549a | Quality-Control Analysis of Generic Nevirapine Formulations in the Developing World: An Initial Report S Penzak1, J Tavel*2, E Acosta3, M Turner3, H Masur1 1Clin Ctr, NIH, Bethesda, MD; 2NIAID, NIH, Bethesda, MD; and 3Div Clin Pharmacol, UAB, Birmingham, AL |